Pacific northwest udall center of excellence clinical consortium

Study design and baseline cohort characteristics

Brenna A. Cholerton, Cyrus P. Zabetian, Joseph Quinn, Kathryn (Kathy) Chung, Amie Peterson, Alberto J. Espay, Fredy J. Revilla, Johnna Devoto, G. Stennis Watson, Shu Ching Hu, Karen L. Edwards, Thomas J. Montine, James B. Leverenz

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: The substantial proportion of individuals with Parkinson's disease (PD) who have or are expected to develop concomitant cognitive impairment emphasizes the need for large, well-characterized participant cohorts to serve as a basis for research into the causes, manifestations, and potential treatments of cognitive decline in those with PD. Objective: To establish a multi-site clinical core that cognitively and clinically characterizes patients with PD by obtaining quality longitudinal clinical, neuropsychological, and validated biomarker data. Methods: Six hundred nineteen participants with idiopathic PD (68.0 ± 9.1 years, 7.1 ± 6.2 years since diagnosis, 70% males) were enrolled in the Pacific Northwest Udall Center (PANUC), one of the Morris K. Udall Centers of Excellence for Parkinson's Research, Clinical Consortium and underwent comprehensive clinical and neuropsychological assessment. Participants were diagnosed with no cognitive impairment (PD-NCI), mild cognitive impairment (PD-MCI), or dementia (PDD) at a diagnostic consensus conference. Results: A substantial proportion of the overall sample was diagnosed with cognitive impairment at baseline: 22% with PDD and 59% with PD-MCI. A higher rate of cognitive impairment was observed in men than women (87% vs. 68%, p <0.0001), despite a higher level of education. Most patients older than 50 years at the time of diagnosis and with disease duration greater than 10 years were cognitively impaired or demented. Conclusions: The PANUC Clinical Consortium is a clinically and cognitively well-characterized cohort of patients with PD. Baseline cohort characteristics demonstrate a high rate of cognitive impairment in the sample, as well as potential sex differences with regard to cognitive diagnosis. The PANUC Clinical Consortium, with its access to biomarker, genetic, and autopsy data, provides an excellent foundation for detailed research related to cognitive impairment in PD.

Original languageEnglish (US)
Pages (from-to)205-214
Number of pages10
JournalJournal of Parkinson's Disease
Volume3
Issue number2
DOIs
StatePublished - 2013

Fingerprint

Northwestern United States
Parkinson Disease
Dementia
Biomarkers
Research
Cognitive Dysfunction
Clinical Studies
Sex Characteristics
Autopsy
Consensus
Education

Keywords

  • Cognition
  • cohort studies
  • dementia
  • mild cognitive impairment
  • movement disorders
  • Parkinson disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Pacific northwest udall center of excellence clinical consortium : Study design and baseline cohort characteristics. / Cholerton, Brenna A.; Zabetian, Cyrus P.; Quinn, Joseph; Chung, Kathryn (Kathy); Peterson, Amie; Espay, Alberto J.; Revilla, Fredy J.; Devoto, Johnna; Stennis Watson, G.; Hu, Shu Ching; Edwards, Karen L.; Montine, Thomas J.; Leverenz, James B.

In: Journal of Parkinson's Disease, Vol. 3, No. 2, 2013, p. 205-214.

Research output: Contribution to journalArticle

Cholerton, BA, Zabetian, CP, Quinn, J, Chung, KK, Peterson, A, Espay, AJ, Revilla, FJ, Devoto, J, Stennis Watson, G, Hu, SC, Edwards, KL, Montine, TJ & Leverenz, JB 2013, 'Pacific northwest udall center of excellence clinical consortium: Study design and baseline cohort characteristics', Journal of Parkinson's Disease, vol. 3, no. 2, pp. 205-214. https://doi.org/10.3233/JPD-130189
Cholerton, Brenna A. ; Zabetian, Cyrus P. ; Quinn, Joseph ; Chung, Kathryn (Kathy) ; Peterson, Amie ; Espay, Alberto J. ; Revilla, Fredy J. ; Devoto, Johnna ; Stennis Watson, G. ; Hu, Shu Ching ; Edwards, Karen L. ; Montine, Thomas J. ; Leverenz, James B. / Pacific northwest udall center of excellence clinical consortium : Study design and baseline cohort characteristics. In: Journal of Parkinson's Disease. 2013 ; Vol. 3, No. 2. pp. 205-214.
@article{800bd3675be54010a143f7f8c34edabf,
title = "Pacific northwest udall center of excellence clinical consortium: Study design and baseline cohort characteristics",
abstract = "Background: The substantial proportion of individuals with Parkinson's disease (PD) who have or are expected to develop concomitant cognitive impairment emphasizes the need for large, well-characterized participant cohorts to serve as a basis for research into the causes, manifestations, and potential treatments of cognitive decline in those with PD. Objective: To establish a multi-site clinical core that cognitively and clinically characterizes patients with PD by obtaining quality longitudinal clinical, neuropsychological, and validated biomarker data. Methods: Six hundred nineteen participants with idiopathic PD (68.0 ± 9.1 years, 7.1 ± 6.2 years since diagnosis, 70{\%} males) were enrolled in the Pacific Northwest Udall Center (PANUC), one of the Morris K. Udall Centers of Excellence for Parkinson's Research, Clinical Consortium and underwent comprehensive clinical and neuropsychological assessment. Participants were diagnosed with no cognitive impairment (PD-NCI), mild cognitive impairment (PD-MCI), or dementia (PDD) at a diagnostic consensus conference. Results: A substantial proportion of the overall sample was diagnosed with cognitive impairment at baseline: 22{\%} with PDD and 59{\%} with PD-MCI. A higher rate of cognitive impairment was observed in men than women (87{\%} vs. 68{\%}, p <0.0001), despite a higher level of education. Most patients older than 50 years at the time of diagnosis and with disease duration greater than 10 years were cognitively impaired or demented. Conclusions: The PANUC Clinical Consortium is a clinically and cognitively well-characterized cohort of patients with PD. Baseline cohort characteristics demonstrate a high rate of cognitive impairment in the sample, as well as potential sex differences with regard to cognitive diagnosis. The PANUC Clinical Consortium, with its access to biomarker, genetic, and autopsy data, provides an excellent foundation for detailed research related to cognitive impairment in PD.",
keywords = "Cognition, cohort studies, dementia, mild cognitive impairment, movement disorders, Parkinson disease",
author = "Cholerton, {Brenna A.} and Zabetian, {Cyrus P.} and Joseph Quinn and Chung, {Kathryn (Kathy)} and Amie Peterson and Espay, {Alberto J.} and Revilla, {Fredy J.} and Johnna Devoto and {Stennis Watson}, G. and Hu, {Shu Ching} and Edwards, {Karen L.} and Montine, {Thomas J.} and Leverenz, {James B.}",
year = "2013",
doi = "10.3233/JPD-130189",
language = "English (US)",
volume = "3",
pages = "205--214",
journal = "Journal of Parkinson's Disease",
issn = "1877-7171",
publisher = "IOS Press",
number = "2",

}

TY - JOUR

T1 - Pacific northwest udall center of excellence clinical consortium

T2 - Study design and baseline cohort characteristics

AU - Cholerton, Brenna A.

AU - Zabetian, Cyrus P.

AU - Quinn, Joseph

AU - Chung, Kathryn (Kathy)

AU - Peterson, Amie

AU - Espay, Alberto J.

AU - Revilla, Fredy J.

AU - Devoto, Johnna

AU - Stennis Watson, G.

AU - Hu, Shu Ching

AU - Edwards, Karen L.

AU - Montine, Thomas J.

AU - Leverenz, James B.

PY - 2013

Y1 - 2013

N2 - Background: The substantial proportion of individuals with Parkinson's disease (PD) who have or are expected to develop concomitant cognitive impairment emphasizes the need for large, well-characterized participant cohorts to serve as a basis for research into the causes, manifestations, and potential treatments of cognitive decline in those with PD. Objective: To establish a multi-site clinical core that cognitively and clinically characterizes patients with PD by obtaining quality longitudinal clinical, neuropsychological, and validated biomarker data. Methods: Six hundred nineteen participants with idiopathic PD (68.0 ± 9.1 years, 7.1 ± 6.2 years since diagnosis, 70% males) were enrolled in the Pacific Northwest Udall Center (PANUC), one of the Morris K. Udall Centers of Excellence for Parkinson's Research, Clinical Consortium and underwent comprehensive clinical and neuropsychological assessment. Participants were diagnosed with no cognitive impairment (PD-NCI), mild cognitive impairment (PD-MCI), or dementia (PDD) at a diagnostic consensus conference. Results: A substantial proportion of the overall sample was diagnosed with cognitive impairment at baseline: 22% with PDD and 59% with PD-MCI. A higher rate of cognitive impairment was observed in men than women (87% vs. 68%, p <0.0001), despite a higher level of education. Most patients older than 50 years at the time of diagnosis and with disease duration greater than 10 years were cognitively impaired or demented. Conclusions: The PANUC Clinical Consortium is a clinically and cognitively well-characterized cohort of patients with PD. Baseline cohort characteristics demonstrate a high rate of cognitive impairment in the sample, as well as potential sex differences with regard to cognitive diagnosis. The PANUC Clinical Consortium, with its access to biomarker, genetic, and autopsy data, provides an excellent foundation for detailed research related to cognitive impairment in PD.

AB - Background: The substantial proportion of individuals with Parkinson's disease (PD) who have or are expected to develop concomitant cognitive impairment emphasizes the need for large, well-characterized participant cohorts to serve as a basis for research into the causes, manifestations, and potential treatments of cognitive decline in those with PD. Objective: To establish a multi-site clinical core that cognitively and clinically characterizes patients with PD by obtaining quality longitudinal clinical, neuropsychological, and validated biomarker data. Methods: Six hundred nineteen participants with idiopathic PD (68.0 ± 9.1 years, 7.1 ± 6.2 years since diagnosis, 70% males) were enrolled in the Pacific Northwest Udall Center (PANUC), one of the Morris K. Udall Centers of Excellence for Parkinson's Research, Clinical Consortium and underwent comprehensive clinical and neuropsychological assessment. Participants were diagnosed with no cognitive impairment (PD-NCI), mild cognitive impairment (PD-MCI), or dementia (PDD) at a diagnostic consensus conference. Results: A substantial proportion of the overall sample was diagnosed with cognitive impairment at baseline: 22% with PDD and 59% with PD-MCI. A higher rate of cognitive impairment was observed in men than women (87% vs. 68%, p <0.0001), despite a higher level of education. Most patients older than 50 years at the time of diagnosis and with disease duration greater than 10 years were cognitively impaired or demented. Conclusions: The PANUC Clinical Consortium is a clinically and cognitively well-characterized cohort of patients with PD. Baseline cohort characteristics demonstrate a high rate of cognitive impairment in the sample, as well as potential sex differences with regard to cognitive diagnosis. The PANUC Clinical Consortium, with its access to biomarker, genetic, and autopsy data, provides an excellent foundation for detailed research related to cognitive impairment in PD.

KW - Cognition

KW - cohort studies

KW - dementia

KW - mild cognitive impairment

KW - movement disorders

KW - Parkinson disease

UR - http://www.scopus.com/inward/record.url?scp=84880221399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880221399&partnerID=8YFLogxK

U2 - 10.3233/JPD-130189

DO - 10.3233/JPD-130189

M3 - Article

VL - 3

SP - 205

EP - 214

JO - Journal of Parkinson's Disease

JF - Journal of Parkinson's Disease

SN - 1877-7171

IS - 2

ER -